No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KRON240719C2500
- 0.12
- 0.000.00%
15min DelayTrading Jun 27 15:19 ET
0.00High0.00Low
0.00Open0.12Pre Close0 Volume287 Open Interest2.50Strike Price0.00Turnover374.79%IV136.04%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.2960Delta0.3685Gamma9.25Leverage Ratio-0.0088Theta0.0001Rho2.74Eff Leverage0.0009Vega
Intraday
- 5D
- Daily
News
Shareholders May Be More Conservative With Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For Now
Increases to Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation Might Cool off for Now
President of Kronos Bio Picks Up 36% More Stock
Insider Spends US$3.1m Buying More Shares In Kronos Bio
12 Health Care Stocks Moving In Thursday's Intraday Session
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
Comments
$Kronos Bio(KRON.US$
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
2
$Kronos Bio(KRON.US$ Kronos Bio Says Phase 1b Portion Of Phase 1b/2 Lanraplenib Study Does Not Support Continuing To Phase 2![]()
3
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
17
7
$Westwater Resources(WWR.US$ go buy these IPO I mentioned few days ago $Kronos Bio(KRON.US$ and $iHuman(IH.US$
5
1
Read more